SUMMARY In a randomised study 25 patients over 50 years of age with non-ischaemic central retinal vein occlusion (CRVO) were assigned to either a treatment (14 patients, isovolaemic haemodilution) or a control group (11 patients, no treatment). After three months eight eyes in patients with haemodilution improved, whereas none of the untreated eyes had better visual acuity (p<001). Thirteen haemodiluted and 11 control patients could be observed for one year. Six eyes of the haemodiluted patients retained a better visual acuity, whereas no improvements had occurred in the control group (p<0025). In fluorescein angiography the lowering of the packed cell volume to 35-32% accelerated the time of maximal venous filling (tmvf) from 17-4 (SEM 1.4) s to 11*4 (SEM 0.9) s (p<O.005). In patients with non-ischaemic CRVO without treatment the passage time did not change. The shortened tmvf reflects a higher blood velocity. Thus isovolaemic haemodilution improves the visual prognosis in non-ischaemic CRVO probably by inducing a higher blood fluidity, which results in higher blood velocity, at least in areas of compromised retinal microcirculation.
treatment). After three months eight eyes in patients with haemodilution improved, whereas none of the untreated eyes had better visual acuity (p<001). Thirteen haemodiluted and 11 control patients could be observed for one year. Six eyes of the haemodiluted patients retained a better visual acuity, whereas no improvements had occurred in the control group (p<0025). In fluorescein angiography the lowering of the packed cell volume to 35-32% accelerated the time of maximal venous filling (tmvf) from 17-4 (SEM 1.4) s to 11*4 (SEM 0.9) s (p<O.005). In patients with non-ischaemic CRVO without treatment the passage time did not change. The shortened tmvf reflects a higher blood velocity. Thus isovolaemic haemodilution improves the visual prognosis in non-ischaemic CRVO probably by inducing a higher blood fluidity, which results in higher blood velocity, at least in areas of compromised retinal microcirculation. In a randomised prospective study" we showed that the visual outcome of patients with CRVO can be improved by isovolaemic haemodilution (IHD). This kind of treatment had been prompted by finding increased whole blood and plasma viscosity in patients with CRVO.7-' But, as our first study' indicated that ischaemic CRVO might respond better to IHD than its nonischaemic counterpart, we also performed this randomised trial to find out whether IHD improves the visual outcome in patients with nonischaemic CRVO in comparison with untreated patients.
Patients and methods
Venous obstructions may be either ischaemic or nonischaemic. This division depends mainly on fluorescein angiographic and ophthalmoscopic criteria.3 I' We chose criteria (Table 1) that were based largely on the findings of Sinclair and Gragoudas'4 but also took into account visual acuity, which has been stressed as an important parameter for the visual Patients with systemic diseases (congestive heart failure despite treatment, renal insufficiency, and respiratory insufficiency of the pink puffer type, anaemia below 38% packed cell volume (PCV), thrombocytosis above 450x 10"/l) insufficient clarity of media, pre-existing macular disease, and psychosocial problems that would not allow an outpatient haemodilution and long-time follow-up were excluded from the study ( Table 2) .
Complete ophthalmic examinations (visual acuity, slit-lamp examination of the anterior segment, gonioscopy, fundus biomicroscopy, applanation tonometry, visual fields (Goldmann), colour photography of the fundus) were done before haemodilution, in the sixth and twelvth week after the beginning of treatment, and thereafter every three months up to one year.
Visual acuity was determined fully refracted at 6 m by examiners who were not involved in the study. A change in visual acuity was considered to be present if the patient could read at least two steps more or less on the scale as shown in Figs. 1 
Results
The randomised study had been planned for 40 patients, but was stopped for ethical reasons after a significant effect became obvious. So only 25 patients were enrolled in the randomised, controlled trial of the effect of IHD in non-ischaemic CRVO. Our classification was done during the first three days after the first presentation of the patient. Two of 14 eyes with non-ischaemic CRVO in haemodiluted patients converted to the ischaemic form (Table 1) in spite of haemodilution, whereas in control patients 4 of 11 eyes developed ischaemic CRVO, three of them within the first two months. These eyes underwent a panretinal photocoagulation, as has been reported elsewhere."
The 25 patients were well matched on entry (Table  2) for sex, age, duration of occlusion, and initial visual acuity. All the patients could be examined after three months and only 24 patients after one year because one patient had meanwhile left the country. Whereas eight of 14 patients with IHD attained a better visual acuity after three months (Fig. 1) , none of the 11 control patients had any visual improvement (p<001). Deterioration occurred in two of the 14 haemodiluted and in four of the 11 control patients. After one year the rates of visual improvement were still the same in both groups and remained Initial Visual Acuity (Fig. 3) . Two weeks later no change had occurred in control eyes (17.1 (SEM 0.8) s, n=8), whereas the tnivf was reduced to 11-4 (SEM 0.9) s (n=10) in haemodiluted patients (p<00005).
The beneficial effect of isovolaemic haemodilution on the visual prognosis of patients with CRVO has been demonstrated before in two controlled studies. 6 The shortcomings of these studies were as follows: (1) the results were mainly based on subjective findings like visual acuity; (2) though both studies paid regard to the type of CRVO, the question whether IHD might also be a useful procedure in non-ischaemic CRVO was not solved. Our first controlled trial of IHD in CRVO showed an effect more often in ischaemic than in non-ischaemic CRVO.
We did not change our treatment scheme,' originally proposed by Wiederholt ct al."' Problems of method and the applicability of lHD in the clinical routine are discussed in a separate paper.'"
One rationale for IHD is the finding of Ring et ar and McGrath et al' that patients with CRVO have higher whole blood and plasma viscosity than normal. These results have been corroborated"'' for patients with ischaemic CRVO. In our measurements of different haemorheological parameters we did not find Theological abnormalities in patients with ischaemic and non-ischaemic CRVO, but, as has been shown also by Heinen et al, the fluidity of whole blood was markedly increased after IHD. ' Irrespective of a normal blood fluidity in patients with CRVO, local theological factors should play a part in the compromised microcirculation of the retina. Independently of the primary event the blood flow decreases in venules and capillaries, thus leading to lower shear rates. It is well known that blood viscosity increases logarithmically with linear increase of PCV at a decrease of the shear rate. The increase of blood viscosity may be enhanced by haemoconcentration (plasma extravasation) and greater rigidity of erythrocytes (local acidosis). Thus a low blood velocity may strengthen a vicious circle and ultimately produce capillary lesions from ischaemia. To answer the question whether local theological disturbances can be influenced by IHD we measured the time for maximal venous filling (tmvf), which reflects the blood velocity in retinal vessels. A decrease of whole blood viscosity shortened tmvf. In control patients with nonischaemic CRVO no change of the passage time could be detected after two weeks. These findings suggest that the shortened tmn,,f is induced by a lower whole blood viscosity and hence demonstrates the local efficacy of IHD.
The visual prognosis of CRVO depends very much on the type of occlusion. A Randomised studies on IHD have shown that an increase in visual acuity is more often seen in haemodiluted than in non-haemodiluted patients. This holds true also for patients with non-ischaemic CRVO, as has been shown by our randomised controlled trial (Figs. 1,2) .
If one considers all our haemodiluted patients,"' improvements are more often seen in eyes with ischaemic CRVO. Nevertheless, the prognosis of non-ischaemic CRVO is still better than that of its ischaemic counterpart. An important measure of a patient's visual acuity is the ability to read. In nonischaemic CRVO without haemodilution the rate of patients having a visual acuity of 6/15 or better fell, indicating that this disease is not as benign as has been claimed by Hayreh."4 This fall could finally be prevented by IHD in most cases.
In conclusion this study has shown that IHD may improve the visual prognosis in non-ischaemic as well as in ischaemic CRVO. The improvement is probably induced by a decrease in whole blood viscosity, which leads to a higher blood velocity in areas of compromised retinal microcirculation. The effect of isovolaemic haemodilution only partly influences the visual prognosis of CRVO because it does not eliminate the cause of the obstruction. 
